Day: March 5, 2021

This Full Spectrum CBD Infused Product Line contains 25mg per Serving (“Bite”) / 600mg per Jar (“Unit”)NEW YORK, NY, March 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has selected First Foods Group, Inc. (OTCQB: FIFG) to manufacture its new, full spectrum CBD infused product line.  Through this Manufacturing partnership, First Foods Group, Inc. (“First Foods”) and Tauriga Sciences, Inc. (“Tauriga”) have created a variety of three...

PLANO, Texas, March 05, 2021 (GLOBE NEWSWIRE) — INTRUSION, Inc. (NASDAQ: INTZ), a leading provider of cyber-attack prevention solutions including zero-days, announced today that Jack Blount, President and CEO, Franklin Byrd, CFO, and Gary Davis, CMO, will participate at the Loop Capital Markets Consumer, Industrials and TMT Conference on Thursday, March 11, 2021, and the 33rd Annual ROTH Conference on Tuesday, March 16, 2021. The leadership team will be available throughout both days to host conference calls with investors participating in the events.Portfolio managers and analysts can request a meeting with management by contacting their sales representative at the respective hosting firms.About INTRUSION, Inc.INTRUSION, Inc. protects any-sized company by leveraging advanced threat intelligence with real-time artificial intelligence...

LOS ANGELES, March 05, 2021 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (Nasdaq: VS) (FRANKFURT:BMVB) today announced a strategic partnership with full-service experiential marketing agency, Frias Agency (“Frias”), to power the technology behind interactive experiences for live events and digital activations.Frias Agency clients include iconic beverage brands from Constellation Brands, such as Corona, Cerveza Modelo, Cerveza Pacifico, Crush, Kim Crawford, Meiomi, Blue Chair Bay, and Casa Noble. Frias also works with major athletes like Canelo Alvarez and sports promoters like Matchroom Boxing and Premier Boxing Champions. The Versus partnership with Frias expects to extend prizing into live sporting events starting Summer 2021 for soccer, boxing, wrestling and MMA, as well as live music festivals and tours.“Versus...

ALBUQUERQUE, N.M., March 05, 2021 (GLOBE NEWSWIRE) — LGI Homes, Inc. today announced the opening of two communities in the greater Albuquerque area, Volterra Village and De La Reina.“The real estate market is booming across the country, and real estate in Albuquerque is no exception,” said Chris Kelly, division president of the company’s West division. “We are excited to help meet the demand of customers looking to own a new home with a brand-new community in Belen, De La Reina, and a return to the thriving community of Volterra Village in east Albuquerque.”LGI Homes recently reopened for sales at Volterra Village, a townhome community just ten minutes east of downtown in the Sandia Foothills. After experiencing success by selling out of all available inventory, LGI Homes purchased the remaining 46 lots and commenced sales in early...

CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to SIG-007 for the treatment of Fabry disease, a progressive, life-threatening lysosomal disease.SIG-007 is comprised of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A, or AGAL. Fabry disease is caused by AGAL deficiency and the accumulation of certain substrates within a patient’s cells, which contribute to multi-organ complications including kidney failure, gastrointestinal symptoms, strokes, and heart disease at a young age.“The current standard...

Piraeus, Greece, March 05, 2021 (GLOBE NEWSWIRE) — GasLog Ltd. (GasLog) (NYSE: GLOG), an international owner, operator and manager of liquefied natural gas (“LNG”) carriers, announced today that its Annual Report on Form 20-F for the fiscal year ended December 31, 2020 (the “Annual Report”) has been filed with the U.S. Securities and Exchange Commission and can be accessed on the Company’s website, http://www.gaslogltd.com, in the “Investor Relations” section under “SEC Filings”.Shareholders may also request a hard copy of the Annual Report, which includes the Company’s complete 2020 audited financial statements, free of charge by contacting:Email: ir@gaslogltd.comPhone: +1-212-223-0643About GasLog Ltd.GasLog is an international owner, operator and manager of LNG carriers providing support to international energy companies as part...

TORONTO, March 05, 2021 (GLOBE NEWSWIRE) — SILO WELLNESS INC., (“Silo Wellness” or the “Company”) (CSE:SILO), is pleased to announce that trading its common shares on the Canadian Securities Exchange (“CSE”) will commence today under the ticker symbol “SILO”. In accordance with the policies of the CSE, Silo Wellness has filed its CSE Form 2A Listing Statement on SEDAR, which provides for additional information regarding Silo Wellness’ business operations.“We are delighted to be trading on the CSE as the next step in Silo Wellness’ journey in the functional mushroom and psychedelics marketplaces and celebrate this important milestone with the team who have worked so diligently to bring Silo Wellness to the public markets,” said Douglas K. Gordon, Chief Executive Officer of Silo Wellness. “By listing on the CSE, investors will now...

Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemiaReports new Phase 2a open label extension clinical trial dataCompany to host conference call and live webcast today at 8:30 a.m. ETBOSTON, March 05, 2021 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today reported financial results for the year ended December 31, 2020 and reviewed recent business highlights.“2020 was a pivotal year for Imara during which we advanced IMR-687 into global Phase 2b clinical trials for sickle cell disease and beta-thalassemia, reported clinical data supporting IMR-687 as a...

TORONTO, March 05, 2021 (GLOBE NEWSWIRE) — Digihost Technology Inc. (“Digihost” or the “Company”) (TSXV: DGHI; OTCQB: HSSHF) is issuing this press release in response to recent market activity and the resulting volatility in its share price. Generally, the Company’s policy is to not comment on its stock price or trading activity unless specifically required to do so by the regulators. However, given the recent volatility and the inquiries made by investors, the Company would like to confirm, and reassure the marketplace, that all material information about the Company’s operations has been disclosed.Michel Amar, the Company’s CEO stated: “The fundamentals of our Company and its operations continue to be strong. Digihost is well capitalized and, with the exception of the non-current portion of premises leases, the Company continues...

WARREN, N.J., March 05, 2021 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will host a virtual investor and analyst epinephrine drug delivery research and development event on Thursday, March 25, 2021 at 9:00 am ET.The event will feature a review of the epinephrine drug delivery program, inclusive of the data from the two Phase 1 PK trials and clinical development strategy, and a Q&A discussion. Presentations will be delivered by members of Aquestive’s senior management team and by two prominent Key Opinion Leaders in the field of allergy disorders:David Fleischer, M.D., Section Head, Pediatric Allergy and Immunology at Children’s...